A complicated new clinical trial could give some hope to Alzheimer’s patients and investors in drug companies. But there are lots of devilish details.
Biogen And Eisai Say Alzheimer’s Drug A Success, Reversing Earlier Result
A complicated new clinical trial could give some hope to Alzheimer’s patients and investors in drug companies. But there are lots of devilish details.